Table 1.
Patient demographics.
| Characteristics | mIHC cohort, n (%) | Reddy et al. cohort, n (%) |
|---|---|---|
| No. of patients | 178 (100) | 496 (100) |
| Age | ||
| Median (range) | 60 (16–84) | |
| <60 | 88 (49) | 205 (43) |
| ≥60 | 90 (51) | 268 (57) |
| ND | 23 | |
| Gender | ||
| Male | 103 (58) | 270 (54) |
| Female | 75 (42) | 226 (46) |
| Molecular subtype | ||
| GCB | 62 (45) | 217 (44) |
| ABC | 55 (40) | 203 (41) |
| Unclassified | 21 (15) | 76 (15) |
| ND | 40 | |
| WHO PS | ||
| 0–1 | 125 (71) | 349 (76) |
| ≥2 | 50 (29) | 112 (24) |
| ND | 3 | 35 |
| Stage | ||
| I–II | 77 (44) | 179 (37) |
| III–IV | 100 (56) | 307 (63) |
| ND | 1 | 10 |
| IPI | ||
| 0–2 | 91 (52) | 212 (55) |
| 3–5 | 84 (48) | 176 (45) |
| ND | 3 | 108 |
| Elevated LDH | ||
| Yes | 113 (65) | 235 (53) |
| No | 62 (35) | 206 (47) |
| ND | 3 | 55 |
| EN | ||
| 0–1 | 122 (73) | 341 (73) |
| ≥2 | 46 (27) | 123 (27) |
| ND | 10 | 32 |
| B-symptoms | ||
| Yes | 65 (38) | |
| No | 108 (62) | |
| ND | 5 | |
| Double expressor | ||
| Yes | 49 (34) | |
| No | 97 (66) | |
| ND | 32 | |
| Double hit | ||
| Yes | 8 (5) | |
| No | 141 (95) | |
| ND | 29 | |
| Treatment | ||
| R-CHOP | 116 (65) | |
| R-CHOEPa | 58 (33) | |
| Otherb | 4 (2) | |
| 5-year PFS | 74% | |
| 5-year OS | 78% | 63% |
Abbreviations: ABC, activated B-cell; GCB, germinal center B; IPI, international prognostic index; LDH, lactate dehydrogenase; EN, extranodal site; R-CHOP, rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone; R-CHOEP, R-CHOP + etoposide.
aPatients <65 years with high-risk features were treated with R-CHOEP-14 and systemic CNS prophylaxis consisting of high-dose methotrexate and high-dose cytarabine.
bOther, one R-CHOP/R-CHEP, one R-CHOP/R-CNOP, one R-CHOP/R-mini-CHOP, one R-ICE (excluded from survival analyses).